United States: Sandoz v. Amgen Supreme Court Decision

On June 12, 2017, the U.S. Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc., Nos. 15-1039, 15-1195, interpreting two provisions of the Biologics Price Competition and Innovation Act (BPCIA).2 Below, a divided Federal Circuit panel held that: (1) a biosimilar applicant is not required to provide its application and manufacturing information to the Reference Product Sponsor (RPS), and the BPCIA contains the "exclusive" remedies for any such failure to comply with this disclosure provision; and (2) a biosimilar applicant may only provide its 180-day notice of commercial marketing after the FDA has licensed the biosimilar.3 On appeal, the Court vacated in part and reversed in part, remanding the cases back to the Federal Circuit for further proceedings.

Justice Thomas authored the opinion with Justice Breyer concurring. The opinion affirmed the portion of the Federal Circuit's decision that an injunction forcing disclosure of an abbreviated Biologics License Application (aBLA) under federal law is unavailable if the biosimilar applicant fails to comply with the "information exchange" provision of the BPCIA. However, the Court declined to rule on what, if any, remedies are available under a state law claim, leaving that issue for remand. The Court also reversed the Federal Circuit's determination that the 180-day notice of commercial marketing provision of the BPCIA is ineffective unless it is provided after a biosimilar applicant receives FDA licensure, holding instead that the applicant may provide notice either before or after receiving FDA approval. The Court's decision still leaves uncertain the question as to whether disclosure of a biosimilar applicant's aBLA prior to commencement of a patent infringement suit is mandatory.

Echoing statements made during oral argument and the Federal Circuit's decision, the Supreme Court's opinion provided a concise, yet detailed, overview of the "complex statutory scheme at issue in these cases."4 Justice Breyer, in his concurrence, noted that while "[t]he Court's interpretation of the statutory terms before us is a reasonable interpretation," the FDA has the Congressional authority to engage in a similar interpretation—to either "depart from, or to modify" the Court's ruling.5

1. The "information exchange" provision does not provide for a federal injunction as a remedy and the issue of what, if any, remedies are available is a question under state law.

Paragraph (l)(2)(A) (the "information exchange" provision) of the BPCIA provides that:

Not later than twenty days after the Secretary notifies the subsection (k) applicant that the application has been accepted for review, the subsection (k) applicant shall provide to the reference product sponsor a copy of the application submitted to the Secretary under subsection (k), and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application.6

The first question addressed by Justice Thomas's opinion was whether the "information exchange" requirement is enforceable by injunction. In answering this question, the Court held that a failure to abide by this provision does not allow for the grant of a federal injunction, but for different reasons than those articulated by the lower court.7 Below, the Federal Circuit held that noncompliance with 42 U.S.C. § 262(l)(2)(A) constituted an act of artificial infringement with remedies available under 35 U.S.C. § 271(e)(4),8 but that § 262(l)(9)(C) provides the exclusive remedies for such a violation.9 The Supreme Court disagreed with this underlying basis of artificial infringement. Stating that the submission of the application itself is the catalyst for artificial infringement, the Court noted that the information to be exchanged merely "assists in identifying which patents will be the subject of the artificial infringement suit."10 The Court further observed that both clauses of § 271(e)(2)(C) support its determination: following the submission of the application, an act of artificial infringement occurs under clause (i) if the applicant made the disclosures; if not, infringement still occurs under clause (ii).11 The Court therefore concluded that an applicant's failure to provide its application and manufacturing information is not an act of artificial infringement, with neither § 271(e)(4) nor § 262(l)(9)(C) providing any remedy for this failure.12 The Court, however, agreed with the Federal Circuit that an immediate declaratory-judgment action under § 262(l)(9) is the appropriate form of federal relief.13 The Court noted that the BPCIA's enforcement scheme is sufficiently detailed to evidence Congress' intent for declaratory-judgment actions to be the RPS's sole remedy, "at least as a matter of federal law."14

While addressing the appropriate remedy under federal law, the Supreme Court declined to resolve the question of whether the information exchange provision is mandatory or conditional, stating that the BPCIA does not "require [them] to decide whether § 262(l)(2)(A) is mandatory or conditional," only whether the applicant supplied the required information.15 Instead, the Court stated that this issue must be addressed in the context of Amgen's state law claims. More specifically, in their first complaint, Amgen brought two claims—both arising under California's unfair competition law—against Sandoz for its failure to abide by § 262(l)(2)(A).17 The Federal Circuit dismissed both claims, holding that California's unfair competition law does not provide a cause of action when a violation of the underlying federal statute specifies the "exclusive" remedy, and that such a failure to disclose is not otherwise "unlawful," as the BPCIA provides a regulatory pathway that expressly contemplates this procedural deviation.18 The Supreme Court held otherwise and remanded. The Court reiterated that any failure by the biosimilar applicant to disclose its application and manufacturing information is not an act of artificial infringement; rather, the act of filing the aBLA itself is the infringing act.19 Therefore, the Court disagreed with the Federal Circuit that § 271(e)(4) and § 262(l)(9)(C) provides the only "exclusive," or even appropriate, remedy for Sandoz's failure to comply with the statute.20 Further, the question of whether Sandoz's failure to participate in the information exchange is "unlawful" under California law also involves the application of state law and cannot be adequately addressed by the provisions of the BPCIA alone.21 Thus, the Federal Circuit erred in its decision by only applying federal law to a state law issue.22

On remand, the Supreme Court requested that the Federal Circuit determine whether California law would view a biosimilar applicant's failure to abide by the information exchange as "unlawful."23 If that answer is yes, or if the court assumes that a state law remedy exists, the Justices believe that the Federal Circuit should next address whether the BPCIA preempts a state law remedy.24 The Court also suggested the Federal Circuit could simply assume a state remedy is available and decide only the issue of preemption.25

2. The "notice" provision does not require biosimilar applicants to give RPSs 180-days advance notice of commercial marketing following FDA licensure.

The second question addressed by the Court was whether an applicant may provide effective notice before FDA licensure, or whether it must wait, as held by the Federal Circuit, until after the biosimilar is licensed. Paragraph (l)(8)(A) (the "notice" provision) provides that "[t]he subsection (k) applicant shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)."26 Below, the Federal Circuit held that a notice by the biosimilar applicant is only effective after the FDA has licensed the biosimilar.27 The Supreme Court reversed.

In reaching the unanimous decision, Justice Thomas employed a textualist analysis. Finding that the phrase "of the biological product licensed under subsection (k)" modifies "commercial marketing," not "notice," the Court held that the biosimilar applicant "may provide notice either before or after receiving FDA approval."28 To bolster its interpretation, the Court observed that the Federal Circuit improperly added a second requirement—"[t]he applicant must provide notice after the FDA licenses the biosimilar and at least 180 days before the applicant markets the biosimilar."29 Further, Justice Thomas observed that a neighboring provision allows for this dual-timing requirement and Congress expressly chose not to implement a similar scheme for § 262(l)(8)(A).30

The Court declined to address Amgen's and Sandoz's policy arguments.31 Although the oral argument featured questions concerning the pragmatic effects of the timing of the notice provision, the Court wrote that "[t]he plausibility of the contentions on both sides illustrates why such disputes are appropriately addressed to Congress, not the courts."32 Specifically noting Amgen's policy arguments may have been more persuasive, the Court concluded that the statute's plain language is the "'primary guide' to Congress' preferred policy."33


While the Supreme Court's decision in Sandoz v. Amgen provides much needed guidance that the 180-day notice of commercial marketing can be provided either before or after FDA approval, and confirms that an injunction forcing compliance with the application disclosure provision of the BPCIA is not available under federal law, it still leaves open the question as to whether disclosure is required. That question will remain open until the Federal Circuit has an opportunity to further consider Amgen's state law unfair competition claims on remand.


1 582 U.S. ____ (2017), available at https://www.supremecourt.gov/opinions/16pdf/15-1039_1b8e.pdf

2 Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-21 (2010); see also 42 U.S.C. § 262(k), (l).

3 Amgen Inc. v. Sandoz Inc., 794 F.3d 1347, 1357-58, 1360-61 (Fed. Cir. 2015).

4 Slip op. at 2.

5 Breyer Concurrence at 1.

6 42 U.S.C. § 262(l)(2)(A) (emphasis added).

7 Slip op. at 10.

8 Amgen, 794 F.3d at 1356.

9 Id. at 1356-57.

10 Slip op. at 11.

11 Id. at 12.

12 Id.

13 Id. at 12-13.

14 Id.

15 Id. at 14-15.

16 Slip op. at 14.

17 Id. at 8 ("A 'business act or practice' is 'unlawful' under the unfair competition law if it violates a rule contained in some other state or federal statute." (citation omitted)).

18 Id. at 13-14.

19 Id.

20 Id. at 14.

21 Id. at 14-15.

22 Slip op. at 15.

23 Id. at 15.

24 Id.

25 Id.

26 42 U.S.C. § 262(l)(8)(A).

27 Amgen, 794 F.3d at 1358.

28 Slip op. at 16.

29 Id. (emphasis in original).

30 Id.

31 Id. at 17-18

32 Id. at 18

33 Id. (quoting McFarland v. Scott, 512 U.S. 849, 865 (1994)(THOMAS, J. dissenting)).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
23 Sep 2018, Seminar, Chicago, United States

Finnegan is a sponsor of the Intellectual Property Owners Association Annual Meeting, supporting the Women in IP Networking Brunch.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions